---
title: Pharmacogenomics - Genetic Basis of Drug Response
type: content
phase: 1
status: complete
priority: high
tags: [pharmacogenomics, genetics, personalized-medicine, CYP450-polymorphisms, drug-response]
created: 2025-11-08
last_modified: 2025-11-08
---

# Pharmacogenomics - Genetic Basis of Drug Response

## Introduction

Pharmacogenomics is the study of how genetic variation affects individual responses to medications. It explains why patients respond differently to the same drug and dose, and provides the foundation for personalized medicine. Understanding pharmacogenomics enables clinicians to select optimal drugs and doses based on a patient's genetic makeup, improving efficacy and reducing adverse effects.

## Core Concepts

### Pharmacogenomics vs. Pharmacogenetics

**Pharmacogenetics**:
- Study of single gene effects on drug response
- Historical term
- Example: CYP2D6 polymorphisms affecting codeine metabolism

**Pharmacogenomics**:
- Genome-wide approach to drug response
- Modern, broader term
- Encompasses multiple genes, pathways, and interactions
- Often used interchangeably with pharmacogenetics

### Clinical Significance

**Why it Matters**:
- **Drug efficacy varies**: 30-70% of patients don't respond to standard therapy
- **ADRs are common**: 6-7% of hospital admissions due to ADRs
- **Many ADRs are preventable**: Genetic testing can identify high-risk patients
- **Cost-effective**: Prevent hospitalizations, reduce trial-and-error prescribing

**Impact Areas**:
1. Drug metabolism (pharmacokinetics)
2. Drug targets (pharmacodynamics)
3. Drug transport
4. Adverse drug reactions
5. Dose requirements

---

## Genetic Variation

### Types of Genetic Variants

**Single Nucleotide Polymorphisms (SNPs)**:
- Most common type (~90% of variation)
- Single base pair change
- Example: CYP2C9*2 (Arg144Cys)

**Insertions/Deletions (Indels)**:
- Addition or removal of DNA segments
- Can cause frameshift mutations

**Copy Number Variations (CNVs)**:
- Duplications or deletions of gene segments
- Example: CYP2D6 gene duplications (ultrarapid metabolizers)

**Tandem Repeats**:
- Repetitive DNA sequences
- Example: TPMT polymorphisms

### Genetic Nomenclature

**Allele Naming**:
- **Wild-type**: *1 (normal function)
- **Variants**: *2, *3, *4, etc. (numbered chronologically as discovered)
- Example: CYP2C9*1 (normal), CYP2C9*2 (reduced function)

**Phenotype Classification**:
1. **Ultrarapid Metabolizer (UM)**: >2 functional copies
2. **Extensive/Normal Metabolizer (EM/NM)**: 2 functional alleles
3. **Intermediate Metabolizer (IM)**: 1 functional allele
4. **Poor Metabolizer (PM)**: 0 functional alleles

**Star Allele System**:
- Standard nomenclature for CYP450 genes
- Defined by specific SNPs or mutations
- Example: CYP2D6*4 (splicing defect, PM phenotype)

---

## Pharmacokinetic Genes

### Cytochrome P450 Enzymes

#### CYP2D6

**Clinical Importance**:
- Metabolizes 25% of drugs
- Highly polymorphic (>100 variants)
- No significant inducers
- 5-10% Caucasians are PMs; 1-2% are UMs

**Phenotypes**:

**Poor Metabolizers (PM)** - 5-10% population:
- **Genotypes**: *4/*4, *4/*5, *5/*5 (null alleles)
- **Clinical effects**:
  - **Substrates**: ↑drug levels → toxicity risk
  - **Prodrugs**: Treatment failure (can't activate)

**Intermediate Metabolizers (IM)** - 10-15%:
- **Genotypes**: *1/*4, *1/*5 (one functional allele)
- Reduced but present enzyme activity

**Extensive Metabolizers (EM)** - 70-80%:
- **Genotypes**: *1/*1 (two functional alleles)
- Normal enzyme activity

**Ultrarapid Metabolizers (UM)** - 1-5% (higher in North Africa, Middle East):
- **Genotypes**: Gene duplications (*1/*1xN, *2/*2xN)
- **Clinical effects**:
  - **Substrates**: ↓drug levels → treatment failure
  - **Prodrugs**: ↑active metabolite → toxicity

**Key Substrates**:

**Prodrugs** (require activation):
- **Codeine** → Morphine
  - PMs: No analgesia
  - UMs: Morphine toxicity, respiratory depression
  - FDA warning: Avoid codeine in UMs, especially children post-tonsillectomy
- **Tramadol** → O-desmethyltramadol
  - PMs: Reduced analgesia
- **Tamoxifen** → Endoxifen (active)
  - PMs: Reduced breast cancer efficacy, worse outcomes

**Drugs Cleared by CYP2D6**:
- **Antidepressants**: TCAs (amitriptyline, nortriptyline), SSRIs (paroxetine, fluoxetine), venlafaxine
  - PMs: ↑levels → toxicity (sedation, anticholinergic effects, arrhythmias)
- **Antipsychotics**: Haloperidol, risperidone, aripiprazole
  - PMs: ↑levels → extrapyramidal symptoms
- **Beta-blockers**: Metoprolol, carvedilol, propranolol
  - PMs: ↑bradycardia, hypotension
- **Opioids**: Oxycodone (partial), hydrocodone

**Clinical Recommendations**:
- **Testing indicated for**: Tamoxifen, codeine (pediatrics), TCAs (if high dose)
- **PM patients**:
  - Avoid prodrugs (use alternatives)
  - Reduce dose of CYP2D6 substrates (often 50%)
- **UM patients**:
  - Avoid prodrugs (especially codeine in children)
  - May need higher doses of substrates

**Inhibitors** (phenoconversion):
- Strong: Fluoxetine, paroxetine, bupropion, quinidine
- Can convert EM → PM phenotype
- Example: Fluoxetine + codeine → no analgesia

#### CYP2C9

**Clinical Importance**:
- Metabolizes warfarin, phenytoin, NSAIDs
- *2 and *3 variants reduce activity
- Caucasians: *2 (10-15%), *3 (5-10%)

**Phenotypes**:

**Poor Metabolizers**:
- **Genotypes**: *2/*2, *2/*3, *3/*3 (2-3% population)
- **CYP2C9*2**: ~12% normal activity
- **CYP2C9*3**: ~5% normal activity

**Intermediate Metabolizers**:
- **Genotypes**: *1/*2, *1/*3 (20-25% population)
- Reduced activity

**Extensive Metabolizers**:
- **Genotypes**: *1/*1 (70-80% population)
- Normal activity

**Key Substrates**:

**Warfarin** (S-warfarin, more potent enantiomer):
- **PMs/IMs**: ↑warfarin sensitivity → ↑bleeding risk
- **Dosing**:
  - *1/*1: Standard dose (5-7 mg/day)
  - *1/*2 or *1/*3: ~20% reduction
  - *2/*2, *2/*3, *3/*3: 30-40% reduction
- Combined with VKORC1 genotyping for optimal dosing

**Phenytoin**:
- **PMs**: ↑levels → toxicity (ataxia, nystagmus)
- Narrow therapeutic index
- May need 50% dose reduction in *3/*3

**NSAIDs**: Celecoxib, diclofenac, ibuprofen
- **PMs**: ↑levels, ↑GI bleeding risk
- Less clinically significant (wide TI)

**Sulfonylureas**: Glipizide, glyburide
- **PMs**: ↑hypoglycemia risk

**Clinical Recommendations**:
- **Warfarin**: FDA-approved pharmacogenomic dosing algorithms
- **Phenytoin**: Consider testing if toxicity or resistance
- **PMs**: Start with lower doses, monitor closely

#### CYP2C19

**Clinical Importance**:
- Metabolizes clopidogrel (prodrug), PPIs, some antidepressants
- *2 (most common loss-of-function) and *17 (gain-of-function)
- Asian populations: 15-20% PMs

**Phenotypes**:

**Poor Metabolizers** (2-5% Caucasians, 15-20% Asians):
- **Genotypes**: *2/*2, *2/*3 (null alleles)
- Cannot activate clopidogrel
- Very slow PPI metabolism

**Intermediate Metabolizers** (20-25%):
- **Genotypes**: *1/*2, *1/*3
- Reduced clopidogrel activation

**Extensive Metabolizers** (35-50%):
- **Genotypes**: *1/*1
- Normal activity

**Rapid Metabolizers** (30-45%):
- **Genotypes**: *1/*17, *17/*17 (increased transcription)
- ↑enzyme activity
- ↑clopidogrel activation, ↓PPI effect

**Ultrarapid Metabolizers**:
- Gene duplications (rare)

**Critical Substrate - Clopidogrel**:

**Mechanism**: Prodrug requiring CYP2C19 activation

**PMs and IMs**:
- ↓active metabolite → ↓antiplatelet effect
- ↑cardiovascular events (MI, stent thrombosis, stroke)
- Especially high risk in acute coronary syndrome, PCI

**FDA Black Box Warning** (2010):
- PMs have reduced effectiveness
- Consider alternative antiplatelet (prasugrel, ticagrelor)

**Clinical Recommendations**:
- **Testing**: Consider in ACS, post-PCI patients
- **PMs/IMs**: Use alternative:
  - Prasugrel (not a prodrug)
  - Ticagrelor (not a prodrug)
  - Higher-dose clopidogrel (limited evidence)
- **RMs**: May have ↑bleeding risk on clopidogrel

**Other Substrates**:

**PPIs** (omeprazole, esomeprazole, lansoprazole):
- **PMs**: ↑PPI levels, ↑efficacy (better acid suppression)
- **RMs**: ↓PPI levels, may need higher doses
- Pantoprazole less dependent on CYP2C19

**Antidepressants** (citalopram, escitalopram, sertraline):
- **PMs**: ↑levels → ↑side effects
- FDA max dose recommendations for citalopram based on genotype

#### CYP3A4/5

**Clinical Importance**:
- Metabolizes 50% of drugs
- Less well-defined genetic polymorphisms
- Extensive variation in activity (10-fold)
- Mostly explained by environmental factors (inducers/inhibitors)

**Genetic Variants**:
- CYP3A5*3 (most common variant)
- CYP3A5 expressers vs. non-expressers
- Clinical impact less clear than CYP2D6, 2C9, 2C19

**Relevance**:
- **Tacrolimus dosing**: CYP3A5 expressers need higher doses
- Most variation due to drug interactions, not genetics

#### Other CYP Enzymes

**CYP1A2**:
- Metabolizes caffeine, clozapine, theophylline
- Influenced more by smoking than genetics
- Limited clinical genetic testing

**CYP2B6**:
- Metabolizes efavirenz, bupropion, methadone
- *6 variant (20-60% in African populations)
- Efavirenz: Higher levels → CNS toxicity in *6/*6

---

### Non-CYP Pharmacokinetic Genes

#### TPMT (Thiopurine S-Methyltransferase)

**Function**: Metabolizes thiopurine drugs

**Drugs**: Azathioprine, 6-mercaptopurine (6-MP), thioguanine

**Phenotypes**:
- **Normal activity**: 90% of population
- **Intermediate activity**: 10% (heterozygous)
- **Deficient activity**: 0.3% (homozygous variant)

**Clinical Significance**:

**Low/Absent TPMT**:
- ↓thiopurine inactivation
- ↑6-thioguanine nucleotides (active, toxic)
- **Severe myelosuppression**: Leukopenia, thrombocytopenia, anemia
- Can be life-threatening

**Recommendations** (CPIC guidelines):
- **Preemptive testing**: Recommended before starting thiopurines
- **Heterozygotes**: Reduce dose to 30-70% of standard
- **Homozygous deficient**: Reduce to 10% or avoid; consider alternative (mycophenolate)

**Testing**:
- Genetic testing or enzyme activity assay
- Widely available, cost-effective

#### UGT1A1 (UDP-Glucuronosyltransferase 1A1)

**Function**: Glucuronidation of drugs and bilirubin

**Key Variant**: UGT1A1*28
- Extra TA repeat in promoter → ↓enzyme expression
- Homozygous: 5-10% of population

**Clinical Conditions**:

**Gilbert Syndrome**:
- UGT1A1*28/*28
- Mild unconjugated hyperbilirubinemia
- Benign condition

**Irinotecan Toxicity**:
- **Drug**: Irinotecan (chemotherapy for colorectal cancer)
- **Metabolism**: UGT1A1 glucuronidates SN-38 (active metabolite)
- **UGT1A1*28/*28 patients**:
  - ↓clearance of SN-38
  - Severe diarrhea, neutropenia
  - FDA recommendation: Consider dose reduction (start at 70-80%)

**Testing**: FDA-approved genetic test available

#### DPYD (Dihydropyrimidine Dehydrogenase)

**Function**: Initial step in fluoropyrimidine catabolism

**Drugs**: 5-fluorouracil (5-FU), capecitabine

**Variants**: >40 variants; *2A most common loss-of-function

**Clinical Significance**:

**DPYD Deficiency** (0.5-1% complete, 3-5% partial):
- ↓5-FU catabolism
- ↑5-FU levels (5-10x higher)
- **Severe toxicity**: Mucositis, diarrhea, neutropenia, hand-foot syndrome
- Can be fatal (mortality ~1%)

**Recommendations** (CPIC):
- **Complete deficiency**: Avoid 5-FU/capecitabine or reduce dose 50%
- **Partial deficiency**: Reduce dose 25-50%

**Testing**: Increasingly recommended before fluoropyrimidine therapy

#### G6PD (Glucose-6-Phosphate Dehydrogenase)

**Function**: Protects RBCs from oxidative stress

**Prevalence**:
- X-linked
- 10-15% in African populations
- Mediterranean, Middle Eastern, Asian populations

**Deficiency Phenotype**:
- **Hemolytic anemia** with oxidative stress

**Trigger Drugs**:
- **Antimalarials**: Primaquine, chloroquine (high doses)
- **Antibiotics**: Sulfonamides, nitrofurantoin, dapsone
- **Others**: Rasburicase, methylene blue

**Clinical Recommendations**:
- **Test** before starting high-risk drugs (especially primaquine)
- **Avoid** oxidant drugs in deficiency
- **Supportive care** if hemolysis occurs

#### SLCO1B1 (Solute Carrier Organic Anion Transporter)

**Function**: Hepatic uptake transporter for statins

**Variant**: SLCO1B1*5 (c.521T>C)
- ↓transporter function
- ↓hepatic uptake → ↑plasma levels

**Clinical Significance**:

**Simvastatin-Induced Myopathy**:
- *5/*5 genotype: 17-fold ↑myopathy risk
- Especially at 80 mg dose (now not recommended)
- FDA warning against 80 mg simvastatin (2011)

**Other Statins**:
- Also affects atorvastatin (less), pravastatin
- Rosuvastatin, fluvastatin less affected

**Recommendations** (CPIC):
- *5/*5 or *15/*15: Avoid simvastatin >20 mg or use alternative statin

---

## Pharmacodynamic Genes

### VKORC1 (Vitamin K Epoxide Reductase Complex 1)

**Function**: Target of warfarin; recycles vitamin K

**Variant**: -1639G>A (promoter polymorphism)
- A allele: ↓enzyme expression → ↑warfarin sensitivity

**Haplotypes**:
- **Group A** (AA genotype): Low VKORC1, high warfarin sensitivity (3-4 mg/day)
- **Group B** (GG genotype): High VKORC1, low sensitivity (6-7 mg/day)

**Clinical Application**:

**Warfarin Dosing**:
- Combined with CYP2C9 genotype
- FDA-approved pharmacogenomic dosing
- Multiple algorithms: Gage, IWPC (International Warfarin Pharmacogenomics Consortium)

**Dosing Algorithm Includes**:
- VKORC1 genotype
- CYP2C9 genotype
- Age, weight, indication
- Target INR
- Concurrent medications

**Effectiveness**:
- ↓time to therapeutic INR
- ↓bleeding complications
- ↓thromboembolic events
- Cost-effectiveness debated

**CYP2C9 + VKORC1 Combined**:
```
High dose needed: CYP2C9*1/*1 + VKORC1 GG
Low dose needed: CYP2C9*3/*3 + VKORC1 AA
```

**Caveat**: DOACs (apixaban, rivaroxaban, dabigatran) don't require genetic testing

### CFTR (Cystic Fibrosis Transmembrane Conductance Regulator)

**Relevance**: Mutations cause cystic fibrosis

**Pharmacogenomic Application**:

**Ivacaftor** (CFTR potentiator):
- Only effective in specific CFTR mutations (G551D, others)
- Genotype-directed therapy
- Dramatically improves lung function in responders

**Lumacaftor/Ivacaftor**:
- For F508del homozygotes (most common CF mutation)
- Genotype-specific indication

### HLA Alleles and Adverse Drug Reactions

**Mechanism**: HLA proteins present drug/metabolite to T cells → immune response

#### HLA-B*57:01 - Abacavir Hypersensitivity

**Drug**: Abacavir (NRTI for HIV)

**HLA-B*57:01 Carriers** (5-8% Caucasians, <1% Asians):
- 50% develop hypersensitivity reaction
- Symptoms: Fever, rash, GI symptoms, respiratory symptoms
- Can be life-threatening
- **Never rechallenge** (can be fatal)

**Non-Carriers**:
- <1% hypersensitivity risk

**Recommendations**:
- **Mandatory screening** before abacavir (FDA black box, CPIC)
- **Positive test**: Contraindicated; use alternative NRTI
- **Standard of care** worldwide
- Reduced hypersensitivity reactions by 90%

#### HLA-B*15:02 - Carbamazepine SJS/TEN

**Drug**: Carbamazepine (anticonvulsant)

**HLA-B*15:02 Carriers**:
- Prevalence: 10-15% in Asian populations (Han Chinese, Thai), rare in Caucasians
- **100-fold ↑risk** of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)
- Severe, life-threatening cutaneous reactions
- Mortality up to 30%

**Recommendations** (FDA, CPIC):
- **Screen** Asian patients before carbamazepine
- **Positive**: Avoid carbamazepine; use alternatives (valproate, levetiracetam, lamotrigine)
- **Note**: Phenytoin, fosphenytoin also associated (weaker evidence)

#### HLA-B*58:01 - Allopurinol SCAR

**Drug**: Allopurinol (xanthine oxidase inhibitor for gout)

**HLA-B*58:01 Carriers**:
- Prevalence: 7-20% in Han Chinese, Koreans, Thais; 2% Caucasians
- **80-fold ↑risk** of severe cutaneous adverse reactions (SCAR)
- SJS/TEN, DRESS syndrome
- Mortality 10-30%

**Recommendations**:
- **Screen** in high-risk populations (Asians, especially with CKD)
- **Positive**: Avoid allopurinol or start very low dose with close monitoring
- **Alternative**: Febuxostat (no HLA association)

#### HLA-A*31:01 - Carbamazepine DRESS

**Association**: Carbamazepine-induced DRESS syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms)

**Prevalence**: European, Japanese populations

**Recommendations**: Screening considered in some populations

#### HLA-DQA1*05:01 - Clozapine Agranulocytosis

**Drug**: Clozapine (atypical antipsychotic)

**Association**: Increased risk of agranulocytosis

**Current Practice**: Mandatory WBC monitoring (not routine genetic testing)

---

## Ethnic and Population Differences

### CYP2D6
- **Caucasians**: 5-10% PMs
- **Africans**: 2-5% PMs
- **Asians**: 1-2% PMs
- **UMs**: Higher in Middle Eastern, North African populations (up to 29%)

### CYP2C19
- **Caucasians**: 2-5% PMs
- **Asians**: 13-23% PMs (highest)
- Clinical significance for clopidogrel in Asian populations

### CYP2C9
- *2 variant: Common in Caucasians, rare in Asians/Africans
- *3 variant: All populations
- Warfarin sensitivity differences

### VKORC1
- A allele frequency:
  - **Asians**: 90%
  - **Caucasians**: 40%
  - **Africans**: 10%
- Explains lower warfarin dose requirements in Asians

### HLA Alleles
- **HLA-B*15:02**: High in Asians (10-15%), rare in Caucasians
- **HLA-B*58:01**: High in Asians (7-20%)
- **HLA-B*57:01**: Higher in Caucasians (5-8%)

**Clinical Implication**: Ethnicity informs testing strategies and drug selection

---

## Clinical Implementation

### Indications for Pharmacogenomic Testing

**Established (Routine Testing Recommended)**:
1. **Abacavir** → HLA-B*57:01 (mandatory)
2. **Carbamazepine** (Asians) → HLA-B*15:02
3. **Thiopurines** → TPMT
4. **Irinotecan** (high dose) → UGT1A1
5. **Fluorouracil** → DPYD (increasingly recommended)
6. **Ivacaftor** → CFTR mutation

**Consider Testing**:
1. **Warfarin** → CYP2C9, VKORC1 (algorithms available)
2. **Clopidogrel** (ACS, PCI) → CYP2C19
3. **Codeine** (pediatric, ultrarapid concern) → CYP2D6
4. **TCAs** (high dose) → CYP2D6
5. **Tamoxifen** → CYP2D6
6. **Simvastatin** (high dose) → SLCO1B1
7. **Allopurinol** (Asian patients) → HLA-B*58:01

**Emerging Applications**:
- Psychiatric medications (CYP2D6, 2C19)
- Pain management (CYP2D6 for opioids)
- Cardiovascular drugs

### Testing Approaches

**Single-Gene Testing**:
- Targeted for specific drug
- Lower cost
- Example: HLA-B*57:01 before abacavir

**Multi-Gene Panels**:
- Test multiple pharmacogenes at once
- Often includes: CYP2D6, 2C9, 2C19, VKORC1, SLCO1B1, TPMT, UGT1A1, HLA alleles
- Cost decreasing with technology advances

**Preemptive Testing**:
- Test before medications needed
- Results stored in EMR
- Alerts trigger when relevant drug prescribed
- Growing trend

**Point-of-Care vs. Send-Out**:
- POC: Rapid (hours), limited genes
- Send-out: Comprehensive, takes days to weeks

### Interpreting Results

**Clinical Pharmacogenetics Implementation Consortium (CPIC)**:
- Evidence-based guidelines
- Gene-drug pairs
- Free, updated regularly
- www.cpicpgx.org

**PharmGKB** (Pharmacogenomics Knowledge Base):
- Comprehensive database
- Drug labels, guidelines, pathways
- www.pharmgkb.org

**FDA Pharmacogenomic Biomarkers in Drug Labeling**:
- Required testing
- Recommended testing
- Informative labeling

### Challenges

**Implementation Barriers**:
1. **Cost**: $200-2000 depending on panel
2. **Insurance coverage**: Variable
3. **Turnaround time**: Days to weeks for many tests
4. **Interpretation complexity**: Requires expertise
5. **EMR integration**: Alerts and decision support needed
6. **Provider education**: Limited pharmacogenomics training

**Ethical Considerations**:
1. Genetic privacy
2. Genetic discrimination concerns
3. Incidental findings
4. Informed consent

---

## Future Directions

### Expanding Applications

**Oncology**:
- Tumor pharmacogenomics (EGFR, KRAS, BRAF mutations)
- Chemotherapy dosing
- Targeted therapy selection

**Psychiatry**:
- Antidepressant selection (GeneSight, others)
- Antipsychotic dosing
- Controversial efficacy

**Cardiovascular**:
- PCSK9 variants
- Statin response prediction

**Infectious Disease**:
- HIV drug selection (beyond abacavir)
- Tuberculosis treatment

### Polygenic Risk Scores

- Multiple genetic variants combined
- Predict complex drug responses
- Not yet clinically validated

### Pharmacoepigenomics

- Epigenetic modifications affecting drug response
- DNA methylation, histone modification
- Emerging field

### Artificial Intelligence

- Machine learning to predict drug response
- Integrate genomic + clinical + environmental data
- Personalized dosing algorithms

---

## Clinical Pearls

1. **HLA-B*57:01 + abacavir**: Mandatory testing, prevents fatal reactions
2. **TPMT testing**: Standard before thiopurines, prevents severe myelosuppression
3. **CYP2C19 PMs**: Poor clopidogrel response → use prasugrel/ticagrelor
4. **CYP2D6 PMs**: Codeine ineffective; TCAs at high risk of toxicity
5. **CYP2C9 + VKORC1**: Warfarin dosing algorithms available
6. **Asian patients + carbamazepine**: Screen HLA-B*15:02
7. **Ultrarapid metabolizers**: Codeine can be toxic (especially children)
8. **Phenoconversion**: Drug interactions can override genetics (e.g., fluoxetine makes EM → PM)
9. **Ethnicity matters**: Different allele frequencies in populations
10. **CPIC guidelines**: Evidence-based resource for gene-drug pairs

---

## Common Exam Topics

1. **CYP2D6 polymorphisms**: Codeine failure in PMs, toxicity in UMs
2. **CYP2C19 + clopidogrel**: Poor response in PMs
3. **HLA-B*57:01 + abacavir**: Hypersensitivity screening
4. **TPMT + azathioprine**: Myelosuppression risk
5. **Warfarin pharmacogenomics**: CYP2C9 + VKORC1
6. **G6PD deficiency**: Hemolysis with oxidant drugs
7. **HLA-B*15:02 + carbamazepine**: SJS/TEN in Asians
8. **UGT1A1 + irinotecan**: Toxicity in *28/*28
9. **Ethnic differences**: CYP2C19 PMs higher in Asians
10. **Phenotype classification**: UM, EM, IM, PM definitions

---

## Key Takeaways

1. **Pharmacogenomics explains variable drug responses** based on genetics
2. **CYP450 polymorphisms** are most clinically relevant (2D6, 2C9, 2C19)
3. **Poor metabolizers**: ↑drug levels (substrates), treatment failure (prodrugs)
4. **Ultrarapid metabolizers**: ↓drug levels (substrates), toxicity (prodrugs)
5. **HLA alleles predict severe ADRs**: Abacavir, carbamazepine, allopurinol
6. **TPMT testing prevents severe myelosuppression** with thiopurines
7. **Clopidogrel less effective in CYP2C19 PMs** → use alternatives
8. **Warfarin dosing** guided by CYP2C9 + VKORC1
9. **Ethnic differences** in allele frequencies affect testing strategies
10. **Preemptive testing** becoming more common
11. **CPIC guidelines** provide evidence-based recommendations
12. **Personalized medicine** is the future of pharmacotherapy

---

## Guidelines and Resources

### Key Guidelines

**CPIC (Clinical Pharmacogenetics Implementation Consortium)**:
- Evidence-based gene-drug guidelines
- Freely available
- Regularly updated

**FDA Pharmacogenomic Biomarkers**:
- Table of Pharmacogenomic Biomarkers in Drug Labeling
- Required vs. recommended testing
- Updated periodically

**PharmGKB**:
- Comprehensive database
- Variant annotations, drug pathways
- Clinical annotations

### Professional Societies

- **ASCPT** (American Society for Clinical Pharmacology and Therapeutics)
- **AACC** (American Association for Clinical Chemistry)
- **ASHP** (American Society of Health-System Pharmacists)

---

## References

1. Katzung's Basic & Clinical Pharmacology, 15th Edition
2. CPIC Guidelines (www.cpicpgx.org)
3. PharmGKB Database (www.pharmgkb.org)
4. FDA Table of Pharmacogenomic Biomarkers in Drug Labeling
5. Roden DM, et al. Pharmacogenomics. Lancet. 2019.
6. Johnson JA, Cavallari LH. Pharmacogenetics and cardiovascular disease. Circulation. 2019.
7. Scott SA, et al. Clinical Pharmacogenetics Implementation Consortium guidelines. Clin Pharmacol Ther. Multiple years.
